What is ALS Phase 2B Study CK-2017357?
CATEGORY:
NCT01378676 is a Phase 2B Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS). Other study ID number is CY 4024.
Save up to 80% off your prescriptions!
How do members experience ALS Phase 2B Study CK-2017357?
Top 5 reported purposes & perceived effectiveness
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Participate in clinical trial | 16 | 19 | |
| Amyotrophic lateral sclerosis | 11 | 17 |
Common side effects
| Side effect | Patients | Percentage |
|---|---|---|
| Dizziness | 6 | |
| Fatigue | 3 | |
| Lightheadedness | 3 | |
| Nausea | 2 | |
| Brain fog | 1 | |
| Daytime tiredness | 1 |
Side effect severity
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 3 | |
| Moderate | 6 | |
| Mild | 9 | |
| None | 8 |
Learn more about our community’s experience with ALS Phase 2B Study CK-2017357
What are people saying about ALS Phase 2B Study CK-2017357?
25
25
members have reported taking ALS Phase 2B Study CK-2017357
Join the conversation and connect with people who have taken ALS Phase 2B Study CK-2017357
Last updated: